Today EuropaBio – the European Association for Bioindustries and Charles River Associates launch the new study “Impact of the EU’s General Pharmaceutical Legislation on Europe’s Innovation Ecosystem and Biotechnology Companies”! This new study highlights the consequences of the General Pharmaceutical Legislation for EU patients and economies within the global race towards healthcare resilience and competitive positioning.
Read the full study: https://lnkd.in/eHZMiaHU